Live Feeds
● LIVE Updated 1h ago · 12 sources tracked

Moderna’s Cancer Vaccine Success Doesn’t Live Up to Early Hype

Moderna and Merck released Phase 3 trial data for their personalized mRNA cancer vaccine, intismeran autogene, combined with the immunotherapy drug Keytruda. The vaccine cut the risk of melanoma recurrence and death by forty-two percent, which barely cleared analysts expectations but fell short of the forty-nine percent reduction seen in earlier Phase 2 testing. Following an earlier data leak, shares of both companies fell as investors digested the trial results. Doctors also raised concerns regarding the treatment's high cost and complex manufacturing process.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~3 min
Speed:
RSS Source map (12)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ The personalized cancer vaccine intismeran autogene combined with Merck's Keytruda cut the risk of melanoma recurrence and death by forty-two percent in Phase 3 trials.
  • ✓ The Phase 3 efficacy result fell below the forty-nine percent risk reduction observed in Phase 2 testing.
  • ✓ Shares of both Moderna and Merck fell as investors digested the trial data.
  • ✓ Doctors expressed concerns regarding the high cost and complex manufacturing process of the vaccine.
🛡️ Source Corroboration: 12 independent reporting domains (95% confidence) ⏱ Read time: ~2 min

What changed

Moderna and Merck posted their Phase 3 clinical trial data early following a leak.

Live updates

  1. Moderna Cancer Vaccine Falls Short of Early Hype

    Moderna and Merck released Phase 3 trial data for their personalized mRNA cancer vaccine, intismeran autogene, combined with the immunotherapy drug Keytruda. The vaccine cut the risk of melanoma recurrence and death by forty-two percent, which barely cleared analysts expectations but fell short of the forty-nine percent reduction seen in earlier Phase 2 testing. Following an earlier data leak, shares of both companies fell as investors digested the trial results. Doctors also raised concerns regarding the treatment's high cost and complex manufacturing process.

    Why it matters

    The experimental treatment represents a major test for personalized mRNA technology outside of infectious diseases. Early buzz had driven high market expectations for the melanoma vaccine. The latest findings leave open questions regarding the applicability of the treatment to tumor types beyond melanoma, weighing on market sentiment.

    What is confirmed

    • The personalized cancer vaccine intismeran autogene combined with Merck's Keytruda cut the risk of melanoma recurrence and death by forty-two percent in Phase 3 trials.
    • The Phase 3 efficacy result fell below the forty-nine percent risk reduction observed in Phase 2 testing.
    • Shares of both Moderna and Merck fell as investors digested the trial data.
    • Doctors expressed concerns regarding the high cost and complex manufacturing process of the vaccine.

    What to watch next

    • Updates on whether the vaccine can be applied to tumor types beyond melanoma
    • Further market reaction and analyst evaluations of the drug's commercial viability
    Sources used for this update (13)
    1. www.marketbeat.com — MRNA News Today | Why did Moderna stock go up today? - MarketBeat
    2. help.naver.com — Futures Flat As Oil Rebounds After Trump's "Energy Ceasefire" Unravels, Memory Stocks Slide | ZeroHedge
    3. The Washington Post — Breakthrough vaccine for the deadliest skin cancer cut risk by almost half
    4. Fierce Biotech — After leak, Merck and Moderna post phase 3 cancer vaccine data early
    5. The New York Times — Melanoma Vaccine Ushers in New Hope for Cancer Patients
    6. Yahoo Finance — Moderna stock extends losses as investors digest melanoma vaccine trial data
    7. WSJ — Moderna’s Cancer Vaccine Success Doesn’t Live Up to Early Hype
    8. WSJ — Moderna Investors Should Brace for More Whiplash
    9. WIRED — New mRNA Vaccine Reduces Risk of Melanoma Recurrence by Over 40 Percent
    10. www.biospace.com — ESMO 2026: Merck, Moderna shares fall as cancer vaccine ...
    11. www.managedhealthcareexecutive.com — 5 things you should know about intismeran, the Moderna-Merck cancer vaccine
    12. www.bgnes.com — Moderna’s Cancer Vaccine Success Falls Short of Early ...
    confidence 95%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community